Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries has successfully concluded the acquisition of 100% stake of Ocular Technologies, Sarl (OTS), a portfolio company of Auven Therapeutics (Auven), on December 15, 2016. OTS owns exclusive, worldwide rights to Seciera (cyclosporine A, 0.09% ophthalmic solution).

Earlier in October, the pharma major had executed definitive agreements through its wholly owned subsidiary for the acquisition of 100% of OTS, a portfolio company of Auven, an international private equity company focused on accelerated development of breakthrough therapeutic drugs.

Sun Pharmaceutical Industries is a pharmaceuticals company. The company's business segments include US Business, Indian Branded Generics Business, Emerging Markets, Global Consumer Healthcare Business and Active Pharmaceutical Ingredients (API).